All In Biotech

NDA 020076 · Dr Reddys Labs SA

Habitrol

Nicotine · Transdermal, Transdermal · Cholinergic Nicotinic Agonist

Last checked: Nov 19, 2026Latest source record: Jan 2, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1991

Nov 27, 1991

Approved uses

3

Original approval plus efficacy supplements

Registered trials

911

103 Phase 3, 74 recruiting

FAERS reports

21,152

11,446 serious, 1,652 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 10, 2026.

Use reduces withdrawal symptoms, including nicotine craving, associated with quitting smoking

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 12, 1999 Supplement 11 · Efficacy Letter
  • Jan 7, 1999 Supplement 13 · Efficacy
  • Nov 27, 1991 Original approval · Type 3 - New Dosage Form
6 products under this application
  • HABITROL · NICOTINE 7MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Over-the-counter
  • HABITROL · NICOTINE 14MG/24HR · Film, Extended Release, Transdermal · Discontinued
  • HABITROL · NICOTINE 14MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Over-the-counter
  • HABITROL · NICOTINE 21MG/24HR · Film, Extended Release, Transdermal · Discontinued
  • HABITROL · NICOTINE 7MG/24HR · Film, Extended Release, Transdermal · Discontinued
  • HABITROL · NICOTINE 21MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Nicotine" as an intervention, any sponsor and status, largest first.

All 911 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective2,249
  • product adhesion issue2,229
  • nicotine dependence1,550
  • treatment noncompliance1,549
  • product quality issue1,332
  • nausea1,289
  • overdose1,121
  • headache909
  • dizziness770
  • foetal exposure during pregnancy759
  • dyspnoea742
  • malaise706

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004224
2005209
2006331
2007426
2008324
2009422
2010491
2011555
2012596
2013510
2014559
20151,205
20161,943
20171,505
20182,663
20191,661
20201,433
20211,235
2022950
2023915
2024989
20251,070
2026936

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5,065 on PubMed

Sponsor: Dr Reddys Labs SA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.